These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29751129)

  • 1. Selective inhibition of Src family kinases by SU6656 increases bone mass by uncoupling bone formation from resorption in mice.
    Thouverey C; Ferrari S; Caverzasio J
    Bone; 2018 Aug; 113():95-104. PubMed ID: 29751129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteogenic effects of a potent Src-over-Abl-selective kinase inhibitor in the mouse.
    Murrills RJ; Fukayama S; Boschelli F; Matteo JJ; Owens J; Golas JM; Patel D; Lane G; Liu YB; Carter L; Jussif J; Spaulding V; Wang YD; Boschelli DH; McKew JC; Li XJ; Lockhead S; Milligan C; Kharode YP; Diesl V; Bai Y; Follettie M; Bex FJ; Komm B; Bodine PV
    J Pharmacol Exp Ther; 2012 Mar; 340(3):676-87. PubMed ID: 22171089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Water extract of Rumex crispus prevents bone loss by inhibiting osteoclastogenesis and inducing osteoblast mineralization.
    Shim KS; Lee B; Ma JY
    BMC Complement Altern Med; 2017 Oct; 17(1):483. PubMed ID: 29070038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of Src family kinases and Aurora kinases by SU6656 modulates CTGF (connective tissue growth factor) expression in an ERK-dependent manner.
    Cicha I; Zitzmann R; Goppelt-Struebe M
    Int J Biochem Cell Biol; 2014 Jan; 46():39-48. PubMed ID: 24275091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice.
    Cheon YH; Kim JY; Baek JM; Ahn SJ; Jun HY; Erkhembaatar M; Kim MS; Lee MS; Oh J
    J Bone Miner Res; 2016 Feb; 31(2):403-15. PubMed ID: 26255791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogens and androgens inhibit association of RANKL with the pre-osteoblast membrane through post-translational mechanisms.
    Martin A; Yu J; Xiong J; Khalid AB; Katzenellenbogen B; Kim SH; Katzenellenbogen JA; Malaivijitnond S; Gabet Y; Krum SA; Frenkel B
    J Cell Physiol; 2017 Dec; 232(12):3798-3807. PubMed ID: 28213978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated Gα11 expression in osteoblast lineage cells promotes osteoclastogenesis and leads to enhanced trabecular bone accrual in response to pamidronate.
    Dela Cruz A; Grynpas MD; Mitchell J
    Am J Physiol Endocrinol Metab; 2016 May; 310(10):E811-20. PubMed ID: 27006198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
    Cai X; Xing J; Long CL; Peng Q; Humphrey MB
    J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.
    O'Sullivan S; Naot D; Callon K; Porteous F; Horne A; Wattie D; Watson M; Cornish J; Browett P; Grey A
    J Bone Miner Res; 2007 Nov; 22(11):1679-89. PubMed ID: 17663639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Src enhances osteogenic differentiation through phosphorylation of Osterix.
    Choi YH; Han Y; Lee SH; Cheong H; Chun KH; Yeo CY; Lee KY
    Mol Cell Endocrinol; 2015 May; 407():85-97. PubMed ID: 25802190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous inhibition of Src and Aurora kinases by SU6656 induces therapeutic synergy in human synovial sarcoma growth, invasion and angiogenesis in vivo.
    Arai R; Tsuda M; Watanabe T; Ose T; Obuse C; Maenaka K; Minami A; Ohba Y
    Eur J Cancer; 2012 Oct; 48(15):2417-30. PubMed ID: 22244830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
    Yang JC; Bai L; Yap S; Gao AC; Kung HJ; Evans CP
    Mol Cancer Ther; 2010 Jun; 9(6):1629-37. PubMed ID: 20484016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.
    Lee YC; Huang CF; Murshed M; Chu K; Araujo JC; Ye X; deCrombrugghe B; Yu-Lee LY; Gallick GE; Lin SH
    Oncogene; 2010 Jun; 29(22):3196-207. PubMed ID: 20228840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deficiency in the phosphatase PHLPP1 suppresses osteoclast-mediated bone resorption and enhances bone formation in mice.
    Mattson AM; Begun DL; Molstad DHH; Meyer MA; Oursler MJ; Westendorf JJ; Bradley EW
    J Biol Chem; 2019 Aug; 294(31):11772-11784. PubMed ID: 31189651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation.
    Koyama H; Nakade O; Takada Y; Kaku T; Lau KH
    J Bone Miner Res; 2002 Jul; 17(7):1219-29. PubMed ID: 12096835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myristoleic acid inhibits osteoclast formation and bone resorption by suppressing the RANKL activation of Src and Pyk2.
    Kwon JO; Jin WJ; Kim B; Kim HH; Lee ZH
    Eur J Pharmacol; 2015 Dec; 768():189-98. PubMed ID: 26528796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sanguiin H-6, a constituent of Rubus parvifolius L., inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis and bone resorption in vitro and prevents tumor necrosis factor-α-induced osteoclast formation in vivo.
    Sakai E; Aoki Y; Yoshimatsu M; Nishishita K; Iwatake M; Fukuma Y; Okamoto K; Tanaka T; Tsukuba T
    Phytomedicine; 2016 Jul; 23(8):828-37. PubMed ID: 27288918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
    Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
    Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.